Login to Your Account



Other News To Note


Thursday, March 7, 2013
• Cylene Pharmaceuticals Inc., of San Diego, said it entered an exclusive, worldwide option and license agreement allowing TetraGene LLC, of Tucson, Ariz., to advance the development of Quarfloxin and Cylene's associated cancer quadruplex-targeting technologies.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription